Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3484800 | 0.91 | — | — | |
| SCHEMBL3484815 | 0.84 | EGFR (0.49) | AHRCCNB2CDK1CCNB1GSK3B | |
| SCHEMBL3484676 | 0.81 | AHR (0.56) | AHREGFRERBB2 | |
| SCHEMBL3484719 | 0.79 | PDE7A (0.50) | PDE7A | |
| SCHEMBL11088266 | 0.77 | AHR (0.49) | AHR | |
| SCHEMBL1964539 | 0.76 | CYP3A4 (0.56) | CYP3A4TSHRPDE7ACYP2C9 | |
| SCHEMBL3484612 | 0.73 | MAOB (0.50) | AHRPDE7AEGFRERBB2 | |
| SCHEMBL3484884 | 0.73 | EIF2AK2 (0.62) | AHRPDE7AEGFRERBB2 | |
| SCHEMBL11028338 | 0.73 | CYP3A4 (0.42) | CYP3A4TSHRPDE7ACYP2C9 | |
| SCHEMBL9517127 | 0.72 | CYP3A4 (0.52) | CYP3A4TSHRPDE7ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | AHR 259/4885CYP3A4 1114/4885TSHR 590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.